<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515550</url>
  </required_header>
  <id_info>
    <org_study_id>20181082</org_study_id>
    <secondary_id>1R21NS107897-01A1</secondary_id>
    <nct_id>NCT04515550</nct_id>
  </id_info>
  <brief_title>Mitochondrial Biomarkers in Huntington's Disease</brief_title>
  <official_title>Longitudinal Biospecimen Collection for Mitochondrial Metabolomics in Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers&#xD;
      for Huntington's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigator-initiated, single-site longitudinal study seeks to assess the utility of&#xD;
      mitochondrial metabolomics -- panels of small molecules that affect mitochondrial function --&#xD;
      to diagnose pre-symptomatic, pre-manifest, and symptomatic Huntington's disease and serve as&#xD;
      biomarkers for HD severity and progression. It also seeks to demonstrate that this novel&#xD;
      biomarker in the blood has comparable value to the same analysis in spinal fluid. This&#xD;
      research study involves 3-4 visits over 18 months. Forty volunteers with HD and 25 volunteers&#xD;
      without HD will be included. Volunteers who have HD will have a physical examination and&#xD;
      blood draw at each study visit. Some participants will also volunteer for optional lumbar&#xD;
      puncture.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Change in Unified Huntington Disease Rating Scale (UHDRS) and UHDRS sub-sections</measure>
    <time_frame>At baseline, 9 months, and 18 months</time_frame>
    <description>This is a questionnaire and neurological examination. Lower values are better than higher values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>At baseline, 9 months, and 18 months</time_frame>
    <description>Zero to 30 point cognitive scale. Higher values are better than lower values.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Huntington's disease (HD)</arm_group_label>
    <description>people with HD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls without HD</arm_group_label>
    <description>people without HD</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>lumbar puncture</intervention_name>
    <description>Some participants will have an optional lumbar puncture</description>
    <arm_group_label>Controls without HD</arm_group_label>
    <arm_group_label>Huntington's disease (HD)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and csf specimens for mitochondrial metabolomics&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of people with HD and controls without HD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20 to 85&#xD;
&#xD;
          -  Montreal Cognitive Assessment score &gt;10&#xD;
&#xD;
          -  HD subjects had onset of HD symptoms after the age of 20&#xD;
&#xD;
          -  HD subjects with Diagnostic Confidence Level (DCL) of 0-3 (pre-symptomatic or&#xD;
             pre-manifest) must have at least 40 CAG repeats on one HTT allele&#xD;
&#xD;
          -  HD subjects with Diagnostic Confidence Level (DCL) of 4 (manifest) must have at least&#xD;
             36 CAG repeats on one HTT allele&#xD;
&#xD;
          -  Controls are asymptomatic without family history of HD or have &lt;36 CAG repeats on both&#xD;
             HTT alleles with family history of HD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HD subjects who did not already have genetic testing are excluded from this study&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant during the study&#xD;
&#xD;
          -  Investigational drugs within 3 months of screening visit&#xD;
&#xD;
          -  Alcohol or illicit drug abuse or dependence&#xD;
&#xD;
          -  Other genetic or neurological disorders&#xD;
&#xD;
          -  Other medical or psychiatric illness that in the investigator's judgement will prevent&#xD;
             ability to tolerate or undergo study procedures&#xD;
&#xD;
          -  For those volunteering for lumbar puncture (LP), bleeding disorders or excessive&#xD;
             bleeding, anticoagulation, aspirin if unable to safely stop taking it at least 7 days&#xD;
             prior to LP, other antiplatelet medications, inability to tolerate LP, allergy to&#xD;
             local anesthetic or chlorhexidine, major lumbar spine deformity, low platelets or&#xD;
             abnormal coagulation factors PT/APTT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Qi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisar Khawam</last_name>
    <phone>216-844-2493</phone>
    <email>Elisar.Khawam@UHhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven Gunzler, MD</last_name>
    <phone>216-844-8685</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Gunzler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Gunzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Steven Gunzler, MD</investigator_full_name>
    <investigator_title>Assistant Professor, Neurology</investigator_title>
  </responsible_party>
  <keyword>Huntington disease</keyword>
  <keyword>Huntington's disease</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

